A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Conditions

• Liver Diseases, Alcoholic

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Not accepted

Interventions

• GSK4532990 — DRUG
  GSK4532990 will be administered
• Placebo — DRUG
  Placebo will be administered

Study Details

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

Key Dates

Start date

Sep 27, 2024

Status verified

Mar 2026

Primary completion

Aug 2, 2027

Completion

Mar 7, 2028

Study Design

Enrollment

393 participants (estimated)

Allocation

NA

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: GSK4532990 Dose 1
• Experimental: GSK4532990 Dose 2
• Experimental: GSK4532990 Dose 3
• Experimental: GSK4532990 Dose 4
• Placebo Comparator: Placebo

Primary Outcome Measure

Number of participants with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Up to 8 weeks ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (27)

Find similar trials in Chandler, AZ

Related Studies

• Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
  Enrolling By Invitation · Johns Hopkins University · Baltimore, Maryland